ARQT Q4 2022 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$2M83.6% margin

Operating Income

-$68M-2310.8% margin

Net Income

-$72M-2432.3% margin

EPS (Diluted)

$-1.24

QoQ Revenue Growth

+308.4%

Cash Flow

Operating Cash Flow

-$71M

Free Cash Flow

-$71M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$449M

Total Liabilities

$240M

Stockholders' Equity

$210M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$2M	-$211,000	+1273.5%
Operating Income	-$68M	-$71M	+4.0%
Net Income	-$72M	-$71M	-1.0%

Revenue Segments

Product

$3M100%